Last reviewed · How we verify
Midodrine + pyridostigmine
Midodrine + pyridostigmine is a Alpha-1 adrenergic agonist + acetylcholinesterase inhibitor combination Small molecule drug developed by Seoul National University Hospital. It is currently FDA-approved for Orthostatic hypotension. Also known as: Combination.
Midodrine and pyridostigmine together increase blood pressure and improve symptoms of orthostatic hypotension by enhancing sympathetic activation and acetylcholine availability.
Midodrine, a small molecule, is used in combination with pyridostigmine to treat conditions associated with spinal cord injury, such as autonomic dysreflexia, and to study baroreceptor integrity, sympathetic integrity, and vagal integrity. The combination of midodrine and pyridostigmine has been studied in clinical trials for its effects on blood pressure and cerebral blood flow in individuals with spinal cord injury.
At a glance
| Generic name | Midodrine + pyridostigmine |
|---|---|
| Also known as | Combination |
| Sponsor | Seoul National University Hospital |
| Drug class | Alpha-1 adrenergic agonist + acetylcholinesterase inhibitor combination |
| Target | Alpha-1 adrenergic receptor; acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Midodrine is an alpha-1 adrenergic agonist that directly increases peripheral vasoconstriction and blood pressure. Pyridostigmine is an acetylcholinesterase inhibitor that enhances parasympathetic tone and can improve blood pressure regulation through central and peripheral mechanisms. The combination is used to address orthostatic hypotension through complementary pathways.
Approved indications
- Orthostatic hypotension
Common side effects
- Supine hypertension
- Piloerection
- Urinary retention
- Headache
- Tremor
Key clinical trials
- The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury (PHASE2)
- Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study (PHASE4)
- Treatment of Orthostatic Hypotension in Autonomic Failure (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Midodrine + pyridostigmine CI brief — competitive landscape report
- Midodrine + pyridostigmine updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI
Frequently asked questions about Midodrine + pyridostigmine
What is Midodrine + pyridostigmine?
How does Midodrine + pyridostigmine work?
What is Midodrine + pyridostigmine used for?
Who makes Midodrine + pyridostigmine?
Is Midodrine + pyridostigmine also known as anything else?
What drug class is Midodrine + pyridostigmine in?
What development phase is Midodrine + pyridostigmine in?
What are the side effects of Midodrine + pyridostigmine?
What does Midodrine + pyridostigmine target?
Related
- Drug class: All Alpha-1 adrenergic agonist + acetylcholinesterase inhibitor combination drugs
- Target: All drugs targeting Alpha-1 adrenergic receptor; acetylcholinesterase
- Manufacturer: Seoul National University Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Orthostatic hypotension
- Also known as: Combination
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing